<em>Hematologic Malignancies Demystified</em>

Hematologic Malignancies Demystified

Downloadable Slides From a 2018 prIME Oncology Meeting Series

View Activity

Activity Features

Downloadable Slides

Activity Overview

prIME Downloadable Slides from the 2018 Hematologic Malignancies Demystified Series.

Provider

This activity is provided by prIME Oncology.

Support

This educational activity is supported by grants from AbbVie Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Novartis Oncology; Seattle Genetics, Inc.; and Takeda Oncology.

Acute Leukemia

Featured Expert: Richard M. Stone, MD

Myelodysplastic Syndromes

Featured Expert: Guillermo Garcia-Manero, MD

Myeloproliferative Neoplasms

Featured Expert: Srdan Verstovsek, MD, PhD

Chronic Myelogenous Leukemia

Featured Expert: Jorge Cortes, MD

Hodgkin Lymphoma

Featured Expert: Barbara Pro, MD

Non-Hodgkin Lymphoma

Featured Expert: Julie Vose, MD, MBA

Chronic Lymphocytic Leukemia

Featured Expert: Susan O'Brien, MD

Multiple Myeloma

Featured Expert: Sagar Lonial, MD

Complications of Transplant

Featured Expert: Sergio Giralt, MD, FACP

Benign Hematology

Featured Expert: Stephan Moll, MD

Learning Objectives

After successful completion of this educational activity, participants should be able to:

Physicians

  • Assess new and emerging data with established treatment options
  • Evaluate safety and efficacy data from recent and ongoing clinical trials
  • Distinguish the adverse event profiles of different options for hematologic malignancies
  • Evaluate expert recommendations for monitoring treatment response and managing adverse events

Nurses

  • Evaluate safety and efficacy data from recent and ongoing clinical trials
  • Identify the most common treatment-associated side effects in hematologic treatment agents and select appropriate strategies for prevention, recognition, and management of these events
  • Evaluate the clinical evidence for, and counsel patients on the importance of, the utilization of cytogenetic markers, minimal residual disease, and other prognostic/predictive tests